MedPath

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

Recruiting
Conditions
Melanoma (Skin)
Registration Number
NCT06400550
Lead Sponsor
University of Texas Southwestern Medical Center
Brief Summary

The goal of this study is to observe metabolic features associated with human melanoma tumors.

Detailed Description

This is a single center, correlative study designed to assess metabolic features of melanoma tumors in patients. The study will involve the collection of melanoma tissue at the time of surgical biopsy or excision. All samples will be assessed by mass spectrometry for metabolomic analysis. A subset of patients will have received \[U-13C\]glucose infusions which will be utilized for isotope tracing metabolic analysis. Relevant clinical data (eg survival, metastasis) will be correlated with metabolic findings.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Patients with known or probable malignant melanoma lesions requiring surgical biopsy or excision.
  • Subjects of all races and ethnic origins over age 18.
Exclusion Criteria
  • Not a surgical candidate
  • Poorly controlled diabetes

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Glucose Utilisation in the TCA cycle5 years

In patients receiving a \[U-13C\]Glucose infusion, assess glucose utilization in the TCA cycle by melanoma tumors (defined as fractional enrichment of 13C-label in TCA metabolites)

Secondary Outcome Measures
NameTimeMethod
Relapse free survival5 years

Defined as the time from surgery to disease recurrence or melanoma-related death, whichever occurs first

Overall Survival5 years

Measured as the time of surgery until death from any cause

Development of Lymph Node or Distant Metastasis5 years

Defined as yes/no for each type of metastasis

Trial Locations

Locations (1)

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath